The goal is to bring a much needed COVID-19 vaccine to emerging and developing nations. The agreement establishes integrated logistics to enable efficient worldwide distribution of COVAXX’s COVID-19 vaccine. The aim is to distribute up to a billion doses of the COVAXX synthetic vaccine worldwide in 2021.
COVAXX, a U.S. company developing a multitope synthetic peptide-based vaccine to fight COVID-19, has announced a global logistics partnership with Maersk, one of the world’s largest shipping and integrated logistics providers. The agreement lays out a framework for all transportation and supply chain services that will be needed to deliver COVAXX’s vaccine candidate UB-612 around the world, once approved by regulatory authorities. Financial terms of the agreement are not disclosed.
COVAXX is developing UB-612 using a high precision, synthetic peptide platform to activate both B-cell and T-cell arms. The investigational vaccine is designed to mimic natural biology and preclinical studies have shown high immunogenicity and levels of neutralizing titers against SARS-CoV-2. The technology platform has been successful in commercializing blood diagnostics as well as safe and effective vaccines for infectious disease in animal health and has been tested in numerous clinical trials for other indications to date…
